导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 22.64% | 308/4773 |
| 近一周 | -0.28% | 1015/5465 |
| 近一月 | -2.98% | 2061/5421 |
| 近一季 | -2.50% | 1397/5231 |
| 近半年 | 21.48% | 195/4920 |
| 近一年 | 22.46% | 406/4394 |
| 近两年 | 127.18% | 380/2954 |
| 近三年 | 79.37% | 247/2253 |
| 成立以来 | 56.29% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-4.50% 3639/4961 |
43.49% 703/5312 |
- - |
- - |
| 2025 | 41.25% 742/4813 |
2.03% 1491/3635 |
3.45% 1008/4076 |
40.32% 763/4524 |
-4.63% 3469/4813 |
| 2024 | 2.89% 1950/3463 |
-3.43% 1502/2808 |
-7.42% 2080/3014 |
13.12% 2236/3129 |
1.74% 1036/3463 |
| 2023 | 4.99% 208/2656 |
14.32% 245/2280 |
0.85% 269/2385 |
-8.26% 1687/2515 |
-0.73% 247/2655 |
| 2022 | -27.62% 1494/2207 |
-16.95% 1165/1919 |
-3.11% 1800/2016 |
-16.77% 1494/2113 |
8.07% 274/2208 |
| 2021 | 2.81% 627/1822 |
-6.91% 1045/1255 |
16.65% 196/1330 |
-10.20% 1215/1466 |
5.43% 294/1822 |
| 2020 | 31.93% 492/1250 |
4.09% 89/1028 |
22.70% 199/1067 |
1.93% 1016/1164 |
1.34% 1037/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 嘉实新兴科技100ETF联接A VS. 长安沪深300非周期A(740101) |